Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Vascular Function in Adults With Down Syndrome (VDS)

29 september 2026 uppdaterad av: University of Nevada, Las Vegas

Adults with Down syndrome (Ds) are often thought to have a lower risk of heart and blood vessel disease because they tend to have lower blood pressure (BP) and fewer heart attacks than people without Ds. However, recent research suggests that heart and blood vessel diseases, including stroke, are becoming a more common cause of death in adults with Ds as life expectancy increases. Despite these findings, studies examining heart and blood vessel health in adults with Ds have produced mixed results, making it difficult to determine their true risk and whether preventive strategies are needed. This study will investigate the health of blood vessels in adults with Ds and compare the results with those of adults without Ds. Healthy blood vessels are important because they help deliver blood and oxygen throughout the body. Changes in blood vessel function and stiffness can occur with aging and may increase the risk of heart disease, stroke, kidney disease, and memory problems. The study aims to determine whether adults with Ds experience changes in blood vessel health that may place them at increased cardiovascular risk. Specifically, the study will: (1) Examine how well blood vessels function in adults with Ds; (2) Measure the stiffness of arteries in adults with Ds; (3) Compare two methods used to assess blood vessel function to determine whether a simpler exercise-based test provides results similar to a commonly used standard test. The findings may improve understanding of cardiovascular risk in adults with Ds and help guide future strategies to promote healthy aging in this population.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This proposal challenges the conventional wisdom that adults with Down syndrome (Ds) are at a lower risk for cardiovascular disease (CVD) because they have low blood pressure and fewer heart attacks than their peers without DS. Recent studies show a larger and increasing contribution of non-congenital CVD (including stroke) to mortality in adults with Ds, likely due to the increased life expectancy. Despite this, studies on traditional cardiovascular risk indicators in adults with DS are conflicting. This currently results in limited urgency for implementing risk-lowering strategies. To address this gap in knowledge and methodology, our overall aim is to demonstrate accelerated vascular aging in adults with Ds, defined by age-related yet Ds-specific endothelial dysfunction and arterial stiffness. Vascular aging directly measures the disease progression towards organ damage, such as the brain and the kidneys, which leads to cardiovascular disease, stroke, and Alzheimer's disease (AD) in the general population. Adults with Ds experience excessive syndrome-specific chronic vascular adaptations, which may accelerate vascular aging. However, this has not yet been investigated.

This project aims to provide a more direct and accurate measure to determine cardiovascular risk by comprehensively characterizing vascular health in adults with Ds compared to adults without Ds.

Aim 1: To identify the effect of Ds on endothelial function. Aim 2: To identify the impact of Ds on arterial stiffness. Aim 3: To compare measurements of endothelial function using a hand grip (HG) exercise protocol and the gold standard flow-mediated dilation protocol (FMD).

A cross-sectional research design is used for all aims and includes a comprehensive evaluation of endothelial function and arterial stiffness. Both participants with Ds and a sex-matched control group of participants without Ds or other intellectual disabilities (from here on, control participants) will be included.

Familiarization. The investigators involve parents/caregivers to provide a supportive environment for participants and to enhance the parent's/caregiver's understanding of the research with videos and practice sessions.

Description of data collection visits. Data collection will be completed in two study visits of maximal 2h each. The investigators will first obtain a signed informed consent form explaining our study procedures, potential risks, and benefits of the study from the participants and/or their legally authorized representative, if present. During the first data collection visit, after discussing the study and potential questions, participants and/or their legally authorized representative will complete the International Physical Activity Questionnaire (IPAQ) to confirm eligibility. Participants will be tested in a postprandial state (>3 h) and will refrain from drinking or eating caffeine and drinking alcohol and from exercise 24 h before both the test days. Females will be studied during the first 3-5 days of menses to control for hormonal variation. Baseline measurements will include anthropometric assessments of height, weight, and circumference. Body composition will be measured with a dual x-ray absorptiometry (DEXA) scan to record forearm composition and mass. For arterial stiffness assessment, participants will lie down while their arterial Pulse Wave Velocity (PWV) and Augmentation Index are measured using a brachial blood pressure monitor (Mobil-O-Graph) and carotid-femoral tonometry (PulsePen). Carotid Beta-Stiffness and intima-media thickness (IMT) will be evaluated via carotid ultrasonography (Hitachi Arietta 70). The second visit will include an assessment of endothelial function. Participants will lie down and perform a 2-minute isometric hand grip test (HG) at 30% of maximum voluntary contraction (MVC), followed by a flow-mediated dilation (FMD) protocol with a cuff occlusion of 50 mmHg above systolic blood pressure on the forearm for 5 minutes. Brachial artery dilation and blood flow will be assessed after HG and FMD using high-resolution ultrasonography (Arietta 70, Hitachi, Tokyo, Japan).

Studietyp

Observationell

Inskrivning (Beräknad)

46

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89154
        • Rekrytering
        • University of Nevada Las Vegas - UNLV
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Thessa Hilgenkamp, PhD
        • Underutredare:
          • Andre Rocha, MSc

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 35 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The population being evaluated by the protocol consists of a convenience sample of individuals with Down syndrome (Ds) between the ages of 18 and 35 years old, and a group of control participants without Ds matched for age and sex, living in the community. 43 participants will be enrolled in the study at UNLV: 23 individuals with Down syndrome and 23 individuals without Down syndrome.

Beskrivning

Inclusion Criteria:

  • between 18 and 35 years old
  • generally healthy
  • sedentary (defined as being involved in less than 30 minutes of moderately-intense physical activity per day)

Additionally, for the participants with Down syndrome:

  • diagnosis of Down syndrome trisomy 21
  • normal thyroid function or stable thyroid function (and medications) for at least 6 months.

Exclusion Criteria:

  • unresolved congenital heart disease;
  • atherosclerotic or other vascular disease (such as blood clot history or clotting disorders);
  • asthma or other pulmonary disease;
  • hypertension (defined as BP >140/90 mmHg); blood pressure below 90/60 mmHg;
  • history of pre-syncope or syncope;
  • diabetes (defined as glycated hemoglobin (HbA1c) of >7.5% or use of glucose-lowering medication);
  • severe obesity (defined as body mass index (BMI) >40);
  • heart medications affecting heart rate, blood pressure, or arterial function, including blood thinners; anti-inflammatory medication, including Nonsteroidal anti-inflammatory drugs (NSAIDS);
  • current smoking;
  • currently pregnant or planning to become pregnant during the study period;
  • currently breastfeeding;
  • unable or unwilling to use an acceptable method of contraception during the study timeframe;
  • positive pregnancy test at screening.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiv: CROSS_SECTIONAL

Kohorter och interventioner

Grupp / Kohort
Down Syndrome

Adults with Down Syndrome

Control group

Age- and sex-matched adults without Down Syndrome

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Carotid-femoral pulse wave velocity (PWV).
Tidsram: Through study completion, on average 4 hours

PWV (m/s) will be measured using small, non-invasive pressure-sensitive transducers that record distension waveforms over superficial arteries like the carotid and femoral artery (PulsePen® DiaTecne - Italia).

Through study completion, on average 4 hours

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Augmentation index
Tidsram: Through study completion, on average 4 hours.

Defined as the ratio of Augmentation Pressure (AP) to the total Pulse Pressure (PP), expressed as %. It will be measured using small, non-invasive pressure-sensitive transducers that record distension waveforms over superficial arteries (PulsePen® DiaTecne - Italia).

Through study completion, on average 4 hours.
Carotid Beta-stiffness
Tidsram: Through study completion, on average 4 hours.

The carotid Beta-stiffness index is a unitless measurement. It quantifies the intrinsic stiffness of the common carotid artery using high-definition ultrasound (Hitachi Arietta 70 system, Tokyo, Japan).

Through study completion, on average 4 hours.
Intima-Media Thickness
Tidsram: Through study completion, on average 4 hours.

An ultrasound-based assessment of intima-media thickness (IMT) for the carotid artery. Thickness will be calculated as the distance (mm) from the leading edge of the intima to the beginning of the adventitial layer of the top and bottom walls.

Through study completion, on average 4 hours.
Change in Blood Flow after isometric hand grip exercise.
Tidsram: Through study completion, on average 4 hours.

Participants will perform a 2-minute isometric hand grip exercise at 30% of MVC. Brachial artery blood flow (mL/min) will be assessed using high-resolution ultrasonography (Arietta 70, Hitachi, Tokyo, Japan) and expressed as a percentage of baseline measurements, normalized to forearm lean mass.

Through study completion, on average 4 hours.
Change in Blood Flow after occlusion
Tidsram: Through study completion, on average 4 hours.

Participants will undergo a flow-mediated dilation (FMD) protocol, in which a pneumatic cuff will be placed around the forearm and inflated to 50 mmHg above systolic levels for 5 minutes. Brachial artery blood flow (mL/min) will be assessed using high-resolution ultrasonography (Arietta 70, Hitachi, Tokyo, Japan) and expressed as a percentage of baseline measurements, normalized to forearm lean mass.

Through study completion, on average 4 hours.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 april 2026

Primärt slutförande (Beräknad)

31 maj 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

1 juni 2026

Först inskickad som uppfyllde QC-kriterierna

1 juni 2026

Första postat (Faktisk)

5 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

De-identified IPD will be made available to other researchers upon request.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera